Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination

NCT04247074 is registered in ClinicalTrials.gov with Galderma R&D as lead sponsor.

NCT NCT04247074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04247074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination
Lead sponsor
Galderma R&D
Phase
Phase 3
Overall status
Completed
Start date
February 10, 2020
Completion date
February 26, 2021
Enrollment
413 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

glabellar frown lines (gl), lateral canthal lines (lcl)